In an announcement today by Sofinnova Ventures, it disclosed the major promotions and addition in its senior team. Dr. Srinivas Akkaraju, MD, PhD. will become the firm's General Manager and Dr. Anand Mehra, MD would advance to the General Partner position.
Dr. Akkaraju, a long time investor in the field of life science, will aggressively devote his time in investing in biopharmaceutical companies using the firm's current financier, Sofinnova Venture Partners VIII. He was the Managing Director of New Leaf Venture Partners and had been a member of the board of major pharmaceutical companies like Intercept Pharmaceutical, Seattle Genetics, Synageva BioPharma, Eyetech Pharmaceuticals and Piramed which was acquired by Roche. Dr. Akkaraju was the Managing Director and co-founder of Panorama Capital and the list of Dr Akkaraju's major participations in renowned companies not only in the pharmaceutical industry continues is quite long and extensive.
Dr. Mehra joined Sofinnova in 2007 as its Principal, and was later promoted to the position of Partner and now to General Partner. He headed Sofinnova's investment into Vicept Therapeutics which acquired Allergen and served as Sofinnova's latest board member at NextWave Pharmaceuticals which acquired Pfizer. Dr. Mehra's long list of achievements continues as he contributes his expertise to his team and the company.
Join the Conversation